AKT1 and breast carcinoma: Liu et al. found that overexpressing miR-22 reduces ACLY expression by binding to the 3′-UTR regions of ACLY, which can block the PI3K/Akt signaling pathway and inhibit the growth and metastasis of breast cancer cells (Figure 2) [120].